Otsuka Reports Positive Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szsi) Prevented Progression to Kidney Failure and Improved Kidney Function in IgA Nephropathy (IgAN)

Submitted by Anonymous on

PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced positive topline full study results from the Phase 3 VISIONARY trial. VOYXACT® (sibeprenlimab-szsi) demonstrated statistically significant stabilization of kidney function, with evidence...

Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C–mutant non-small cell lung cancer

Submitted by Anonymous on

Kirsten rat sarcoma viral oncogene (KRAS) G12C inhibitors have demonstrated clinical efficacy against KRAS G12C–mutant non-small cell lung cancer (NSCLC); however, intrinsic and acquired resistance limit their therapeutic potential. Therefore, combination strategies are needed to address these limitations. While various...

Otsuka Holdings Co., Ltd - Otsuka Reports Positive Phase 3 Visionary Two-Year Egfr Results For Voyxact In Igan

Submitted by Anonymous on

Otsuka Holdings Co., Ltd TSE:4578: Otsuka Holdings Co., Ltd - Otsuka Reports Positive Phase 3 Visionary Two-Year Egfr Results For Voyxact In IganRefinitiv Sign up to read this newsJoin for freeMore news from Reuters [Additional Text]: Reuters

Otsuka Reports Positive Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szsi) Prevented Progression to Kidney Failure and Improved Kidney Function in IgA Nephropathy (IgAN)

Submitted by Anonymous on

PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Jul 1, 2026-- Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced positive topline full study results from the Phase 3 VISIONARY trial. VOYXACT ® (sibeprenlimab-szsi) demonstrated statistically significant stabilization of...

Otsuka Reports Positive Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szs

Submitted by Anonymous on

INDICATION and IMPORTANT SAFETY INFORMATION for VOYXACT® (sibeprenlimab-szsi) INDICATION VOYXACT is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. This indication is approved under accelerated approval based on reduction of proteinuria....

Otsuka Reports Positive Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szsi) Prevented Progression to Kidney Failure and Improved Kidney Function in IgA Nephropathy (IgAN)

Submitted by Anonymous on

PRINCETON, N.J. & TOKYO, July 01, 2026--Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced positive topline full study results from the Phase 3 VISIONARY trial. VOYXACT® (sibeprenlimab-szsi) demonstrated statistically significant stabilization of kidney function,...

Coordinated DNA 5-mC and RNA m5C methylation epigenetically regulates MZF1 splice variants to drive EGFR-TKI resistance

Submitted by Anonymous on

Acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) severely limits clinical efficacy. Myeloid zinc finger 1 (MZF1) inhibited EGFR phosphorylation and internalization by maintaining zinc homeostasis, which suggested its potential as a therapeutic target for resensitization. The two...

4-Methylumbelliferone for type 1 diabetes therapy: evidence for β-cell protection via EGFR/PI3K/Akt signaling

Submitted by Anonymous on

AbstractPurpose Type 1 diabetes mellitus (T1DM) results from autoimmune-mediated destruction of pancreatic β-cells, leading to absolute insulin deficiency. Current treatments rely on insulin replacement and do not prevent β-cell loss. 4-Methylumbelliferone (4-MU), an inhibitor of hyaluronan synthesis, has shown anti-inflammatory...

Acquired resistance to first-line osimertinib is heterogeneous in EGFR-mutant advanced non-small cell lung cancer

Submitted by Anonymous on

Osimertinib, a third-generation EGFR tyrosine kinase inhibitor (EGFR-TKI), has shown remarkable efficacy in EGFR-mutant non-small cell lung cancer (NSCLC). However, acquired resistance remains inevitable. This study aimed to explore the underlying resistance mechanisms and evaluate second-line treatment strategies to improve...

Subscribe to Newsfeed